Retatrutide Shows Strong Efficacy and Safety for Obesity Treatment in Clinical Trials

Obesity is a complex, chronic disease affecting millions globally, significantly increasing the risk of serious comorbidities such as type 2 diabetes, cardiovascular disease, and certain cancers. Despite various therapeutic options, many individuals struggle to achieve and maintain substantial weight loss. This systematic review aimed to comprehensively evaluate the efficacy and safety profile of the novel triple-agonist retatrutide across existing clinical trials, addressing the need for more effective and well-tolerated treatments.

The systematic review consistently demonstrated retatrutide's robust efficacy in promoting significant weight loss across the included trials. Participants treated with retatrutide achieved an average body weight reduction of 18% to 24% from baseline, significantly more than placebo groups (p<0.001). The most important finding was that high-dose retatrutide (12 mg once weekly) consistently led to a 22.5% mean weight loss at 48 weeks, representing a 2.5-fold greater reduction compared to lower doses or other GLP-1 agonists. Furthermore, retatrutide improved several metabolic markers, including a 30% reduction in fasting glucose and a 15% decrease in HbA1c, alongside favorable changes in lipid profiles. The safety profile was generally consistent with other incretin-based therapies, with gastrointestinal adverse events (e.g., nausea, diarrhea) being the most common, typically mild to moderate and transient, affecting ~70% of participants.